Alex Zhavoronkov

Bio:

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in generative artificial intelligence technologies for drug discovery and biomarker development. Dr. Zhavoronkov has a combined background in biomedicine and computer technology. He has been recognized by Deep Knowledge Analytics in 2019 as one of the top 100 AI leaders in drug discovery and advanced healthcare globally and has been selected as one of Clarivate's Global Highly Cited Scientists for 2022.

Dr. Zhavoronkov founded Insilico in 2014 and applied AI technologies to analyze a wide range of data types, including anti-aging, disease mechanisms, target identification, and signaling pathway modeling. In 2016, he pioneered the application of key technologies in Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) to drug discovery, discovering novel targets and generating novel molecules with satisfied properties.

Prior to Insilico, Dr. Zhavoronkov worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroGNeuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 200 peer-reviewed research papers, and 3 books. He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, npj Agingand co-chairs the Annual Aging Research, Drug Discovery and AI Forum, the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.